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S-phase checkpoints are triggered in tumor cells in response to DNA replication stress caused by the tumor
microenvironment or oncogenes. A recent report from our laboratory showed that tumor cells and more normal
epithelial cells have a very different response to replication stress. In this Author’s View, the implications of this ﬁnding
are discussed.
Genome instability is now widely rec-
ognized as a critical driver of tumor devel-
opment, having reached the status of one
of the hallmarks of cancer. Events leading
to genetic instability are initiated by DNA
damage or DNA replication stress induced
by exposure to exogenous or endogenous
agents that modify DNA structure. How-
ever, there is also growing evidence that
oncogenes cause DNA replication stress
through alteration of DNA synthesis pre-
cursor pools1 or by inappropriately driv-
ing pre-tumor cells into S phase.2
Nevertheless, cells can deal with such
stresses through DNA repair mechanisms
that recognize and correct DNA damage
and DNA damage responses that trigger
cell cycle arrest, resolve structures blocking
replication, or commit cells to death if the
damage is too great.3
DNA damage response pathways have
been most widely studied in tumor cells
because of the importance of these path-
ways in ensuring tumor cell survival in
hostile environments (e.g., hypoxia or
nutrient deprivation). These studies pro-
vide evidence for a number of different
responses to DNA replication stress
induced by these conditions4 (Fig. 1).
Prominent among replication fork
responses is uncoupling of the replication
and helicase complexes at forks when rep-
lication is disrupted. This leads to the for-
mation of stretches of single-stranded
DNA (ssDNA) that become coated by the
replication protein A complex (RPA). In
turn, RPA–ssDNA provides a substrate
for recruitment of ataxia telangiectasia-
mutated and RAD3-related (ATR) pro-
tein through the ATR interacting protein
(ATRIP) and a host of other factors to
activate the ATR-checkpoint kinase 1
(CHK1) signaling cascade.5 Another
potential response is fork collapse. This
may occur through cleavage of ssDNA
regions that are insufficiently protected by
RPA by structure-specific endonucleases6
or by replication through abasic lesions in
DNA that can be generated by reactive
oxygen species (ROS) in tumor cells.
Depending on the structure of the col-
lapsed fork and its processing, such events
trigger activation of ataxia telangiectasia-
mutated (ATM) or ATR signaling cas-
cades. An alternative fate is reversal of
slowed or arrested replication forks to
form so-called chicken foot structures that
facilitate bypass of damaged DNA or diffi-
cult to replicate DNA. Again, depending
on how such structures are processed,
ATM and/or ATR signaling cascades can
be activated. Most studies of tumor cells
indicate that ATR-CHK1 signaling is pri-
marily activated, suggesting that ssDNA is
a key intermediate at arrested forks. This
is supported by numerous studies demon-
strating formation of RPA foci and
ssDNA. Additionally, many studies have
shown that ATR-CHK1 signaling (but
not ATM) is a crucial determinant of rep-
lication fork and cell fate, as inhibitors of
these checkpoint kinases trigger fork col-
lapse and/or apoptosis.6,7 In some tumor
cell lines these fates require co-treatment
with replication inhibitors whereas in
others the checkpoint inhibitors are effec-
tive as single agents.
In our recent paper,8 we sought to
determine how more normal cells respond
to replication stress. Surprisingly little is
known about the response of normal epi-
thelial cells despite the epithelial origin of
most tumors. Our evidence indicated that
the ATR-CHK1 signaling pathway was
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not activated when human telomerase
reverse transcriptase-immortalized normal
human urothelial (hTERT-NHU) cells
were treated with replication inhibitors.
Critical downstream targets of ATR
(CHK1-Ser345 and RPA2-Ser33) were
not phosphorylated and the formation
of RAD51 foci (which are normally
generated by replication stress in an
ATR-CHK1–dependent manner) was
suppressed. In contrast, the ATM signal-
ing cascade was activated within 2 hours
of treatment. S-phase progression was
slowed in these cells but there was no
induction of apoptosis. Consistent with
the failure to activate CHK1, CHK1
inhibitors had little effect on these cells in
the presence or absence of the replication
inhibitors. In contrast, a highly malignant
bladder cancer cell line (EJ) showed rapid
activation of the ATR-CHK1 signaling
cascade and acute sensitivity to CHK1
inhibitors. The response of the hTERT-
NHU cells is similar to that of human
embryonic stem cells, which also fail to
activate CHK1, induce RAD51 foci, or
generate ssDNA following replication
stress.9 Also, CHK1 inhibitors have little
effect on these cells. So how do ATM
inhibitors affect hTERT-NHU cells
exposed to replication stress? Unexpect-
edly, our evidence suggests that they trig-
ger a G1 checkpoint instead of S-phase
arrest. This response may be a conse-
quence of the role of ATM in controlling
ROS generation; when ATM is inhibited
ROS accumulation could
trigger a G1 checkpoint.10
However, a ROS inhibitor
did not relieve the G1 block
and this is a question that
requires further investiga-
tion. Interestingly, EJ blad-
der tumor cells do not arrest
in G1 after treatment with
the ATM inhibitor (and we
have not found any reports
in the literature of such an
arrest in tumor cells), but
show a weak accumulation in
S phase following treatment
with the ATM inhibitor
alone and robust induction
of apoptosis following treat-
ment with a combination of
ATM and replication
inhibitors.
These findings lead us to
speculate that replication
forks in non-tumor cells
may respond differently to
fork arrest than those in
tumor cells. The formation
of ssDNA appears to be
suppressed, suggesting that
events such as the uncou-
pling of replication and
helicase complexes that
trigger ATR-CHK1 signal-
ing may be more tightly
controlled in hTERT-
NHU. Whether this indi-
cates that non-tumor cells
have specific mechanisms
to prevent polymerase-helicase uncou-
pling is an interesting question that
deserves further study. And do these
findings have any implications for ther-
apy? They suggest that CHK1, and pos-
sibly ATM, inhibitors are particularly
effective in preferentially killing at least
some types of tumor cells. However,
responses to these inhibitors are very
diverse, underlining once again the
need for biomarkers that will predict
which tumor cells will respond.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were
disclosed
Figure 1. Fate of DNA replication forks in response to DNA damage or replication stress. Some forms of DNA dam-
age such as abasic sites that may arise through the action of ROS can directly cause replication fork collapse. Such
events trigger the activation of ATM or ATR, depending on the processing of the end by the MRE11/RAD50/NBS1
(MRN) complex or other DNA damage response proteins that may be recruited to the collapsed fork. Uncoupling
of polymerase and helicase complexes at arrested forks can lead to the formation of stretches of ssDNA. These
become coated with RPA, which then recruits ATRIP and ATR and a number of other proteins to activate the ATR-
CHK1 protein kinase cascade. If ssDNA is insufﬁciently protected by RPA, structure-speciﬁc endonucleases such as
MUS81 can cleave ssDNA to collapse the fork. Arrested forks may also undergo regression to produce the so-called
chicken foot structure. This response potentially enables replication complexes to bypass DNA lesions or difﬁcult
to replicate regions. This structure also produces a substrate for the 30–50 exonuclease activity of MRE11 that can
activate ATM. Regressed forks can also be resolved by a number of other pathways that generate DSBs or ssDNA
to restart DNA synthesis. ATM, ataxia telangiectasia-mutated; ATR, ATM and Rad3 related; CHK1, checkpoint kinase
1; DSBs, DNA double-strand breaks; ROS, reactive oxygen species; RPA, replication protein A; ssDNA, single-
stranded DNA.
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